<DOC>
	<DOCNO>NCT01594723</DOCNO>
	<brief_summary>The primary purpose study measure response rate participant myeloproliferative neoplasm ( MPNs ) , polycythemia vera ( PV ) , essential thrombocythemia ( ET ) , myelofibrosis ( MF ) treat LY2784544 , include demonstrate intolerance , failure primary response , demonstrate disease progression ruxolitinib .</brief_summary>
	<brief_title>A Study LY2784544 Participants With Myeloproliferative Neoplasms</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<criteria>Have diagnosis polycythemia vera ( PV ) , essential thrombocythemia ( ET ) , myelofibrosis ( MF ) define World Health Organization ( WHO ) diagnostic criterion myeloproliferative neoplasm ( Swerdlow et al . 2008 ) meet follow additional subtype specific criterion : PV : fail intolerant standard therapy refuse take standard medication ET : fail intolerant standard therapy refuse take standard medication MF ( participant MF must meet least 1 follow ) : intermediate 1 , intermediate 2 , highrisk MF accord Dynamic International Prognostic Scoring System ( DIPPS Plus ) Primary Myelofibrosis ( Gangat et al . 2011 ) ; symptomatic MF spleen great 10 centimeter ( cm ) leave costal margin ; postpolycythemic MF ; postET MF All PV , ET , MF participant must meet following criterion : Have quantifiable level janus kinase 2 valine phenylalanine substitution amino acid 617 ( JAK2 V617F ) mutation . This inclusion criterion apply subset participant Cohorts 10 11 must negative JAK2 V617F mutation Are ≥ 18 year age Have give write informed consent prior studyspecific procedure Have adequate organ function , include : Hepatic : Direct bilirubin ≤1.5 time upper limit normal ( ULN ) , alanine transaminase ( ALT ) , aspartate transaminase ( AST ) ≤2.5 time ULN ; Renal : Serum creatinine ≤1.5 time ULN ; Bone Marrow Reserve : Absolute neutrophil count ( ANC ) ≥1000/microliter ( mcL ) , platelet ≥50,000/mcL participant ET PV ≥25,000/mcL participant MF Have performance status 0 , 1 , 2 Eastern Cooperative Oncology Group ( ECOG ) scale Have discontinue previous approved therapy Myeloproliferative Neoplasms ( MPNs ) , include chemotherapy , immunomodulating therapy ( example , thalidomide , interferonalpha ) , immunosuppressive therapy ( example , corticosteroid &gt; 10 mg/day prednisone equivalent ) , radiotherapy , erythropoietin , thrombopoietin , granulocyte colony stimulate factor least 14 day recover acute effect therapy . Hydroxyurea use control blood cell count permit study entry subject maintain stable dose least 4 week . Lowdose acetylsalicylic acid ( aspirin ) permit well Are reliable willing make available duration study willing follow study procedure Males female reproductive potential must agree use medically approve contraceptive precaution study 3 month follow last dose study drug Females childbearing potential must negative urine pregnancy test ≤ 7 day first dose study drug must also breastfeed Are able swallow capsule For participant undergone recent major surgery , least 28 day must elapse surgery study participation participant must achieve , opinion treat physician , least good recovery surgical procedure Enrollment Cohort 12 limit MF , PV , ET participant , regardless mutational status , , addition criterion , demonstrate intolerance ruxolitinib , failure primary response ruxolitinib , demonstrate disease progression ruxolitinib Are currently enrol , discontinue within last 14 day clinical trial involve investigational product nonapproved use drug device , concurrently enrol type medical research judge scientifically medically compatible study Have correct QT ( QTc ) interval &gt; 470 millisecond ( msec ) use Bazett 's formula Have serious preexist medical condition , opinion investigator would preclude participation study ( example gastrointestinal disorder cause clinically significant symptom nausea , vomit , diarrhea , malabsorption syndrome ) Are currently treat agent metabolize Cytochrome P450 3A4 enzyme ( CYP3A4 ) narrow therapeutic margin ( example , alfentanil , cyclosporine , diergotamine , ergotamine , fentanyl , pimozide , quinidine , sirolimus , tacrolimus ) Cytochrome P450 2B6 enzyme ( CYP2B6 ) ( example , cyclophosphamide , ifosfamide , tamoxifen , efavirenz , propofol , methadone , bupropion ) Are currently treat warfarin one derivatives know alter level protein C protein S. An exception criterion allow participant prior history BuddChiari Syndrome treat warfarin one derivative Have receive hematopoietic stem cell transplant Have second primary malignancy judgment Investigator Sponsor may affect interpretation result Have active fungal , bacterial , and/or know viral infection include human immunodeficiency virus ( HIV ) viral ( A , B , C ) hepatitis ( screen require ) Have history congestive heart failure New York Heart Association ( NYHA ) Class &gt; 2 ( NYHA Class 1 2 eligible ) , unstable angina , recent myocardial infarction ( within 6 month prior administration study drug ) , document history ventricular arrhythmia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>